Bank Pictet & Cie Europe AG Boosts Holdings in Gilead Sciences, Inc. $GILD

Bank Pictet & Cie Europe AG lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 502.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 15,288 shares of the biopharmaceutical company’s stock after buying an additional 12,752 shares during the quarter. Bank Pictet & Cie Europe AG’s holdings in Gilead Sciences were worth $1,697,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. Invesco Ltd. grew its position in shares of Gilead Sciences by 33.5% in the 2nd quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock worth $1,499,098,000 after buying an additional 3,394,330 shares during the period. Sivik Global Healthcare LLC lifted its position in Gilead Sciences by 25.0% during the 2nd quarter. Sivik Global Healthcare LLC now owns 50,000 shares of the biopharmaceutical company’s stock valued at $5,544,000 after acquiring an additional 10,000 shares during the period. One Wealth Advisors LLC boosted its stake in Gilead Sciences by 34.8% during the second quarter. One Wealth Advisors LLC now owns 9,163 shares of the biopharmaceutical company’s stock worth $1,016,000 after acquiring an additional 2,364 shares in the last quarter. Lombard Odier Asset Management Switzerland SA grew its holdings in Gilead Sciences by 24.6% in the second quarter. Lombard Odier Asset Management Switzerland SA now owns 53,312 shares of the biopharmaceutical company’s stock worth $5,911,000 after purchasing an additional 10,535 shares during the period. Finally, Jump Financial LLC bought a new position in shares of Gilead Sciences during the second quarter valued at approximately $6,988,000. 83.67% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Rothschild & Co Redburn boosted their price target on Gilead Sciences from $143.00 to $153.00 in a research report on Monday, November 10th. The Goldman Sachs Group lifted their price objective on Gilead Sciences from $108.00 to $110.00 and gave the company a “neutral” rating in a research note on Friday, October 31st. Dbs Bank raised Gilead Sciences to a “moderate buy” rating in a research note on Friday, September 5th. Citigroup raised their price target on Gilead Sciences from $125.00 to $135.00 and gave the company a “buy” rating in a report on Wednesday, October 8th. Finally, Scotiabank assumed coverage on Gilead Sciences in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $140.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and an average target price of $131.68.

Gilead Sciences Stock Down 0.4%

GILD stock opened at $122.74 on Friday. The stock has a market capitalization of $152.28 billion, a P/E ratio of 19.03, a P/E/G ratio of 0.68 and a beta of 0.33. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. Gilead Sciences, Inc. has a 1-year low of $88.57 and a 1-year high of $128.70. The business has a fifty day moving average price of $123.04 and a 200-day moving average price of $116.97.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The company had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. During the same period last year, the company earned $2.02 EPS. Gilead Sciences’s revenue for the quarter was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th were issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.6%. The ex-dividend date of this dividend was Monday, December 15th. Gilead Sciences’s payout ratio is presently 48.99%.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $122.00, for a total transaction of $366,000.00. Following the transaction, the chief financial officer owned 153,503 shares in the company, valued at $18,727,366. This represents a 1.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $125.08, for a total transaction of $625,400.00. Following the completion of the sale, the director directly owned 8,920 shares of the company’s stock, valued at approximately $1,115,713.60. This trade represents a 35.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 136,257 shares of company stock valued at $16,855,192 over the last quarter. 0.27% of the stock is owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.